Sibu Hospital is the second largest hospital in the state of Sarawak, Malaysia. This hospital is the secondary referral centre for eight district hospitals located in the central region of Sarawak, namely Kanowit, Kapit, Mukah, Dalat, Daro, Sarikei, Saratok, and Betong.

There are 534 (capacity - 750) beds in Hospital Sibu.

During the past decade, Hospital Sibu conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 7 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 5 clinical trials were completed. i.e. 62.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Sibu" #1 sponsor was "Janssen Research & Development, LLC" with 5 trials, followed by "Clinical Research Centre, Malaysia" with 4 trials sponsored, "Baxalta now part of Shire" with 2 trials sponsored, "Ministry of Health, Malaysia" with 2 trials sponsored and "Ark Biosciences Inc." with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Sibu" #1 collaborator was "Twin Catalyst Sdn. Bhd." with 2 trials as a collaborator, "Ark Biosciences Pty Ltd." with 1 trials as a collaborator, "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Hexal AG" with 1 trials as a collaborator and "Novotech (Australia) Pty Limited" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Sibu" are "Hemophilia A" (2 trials), "Adnexal Mass" (1 trials), "Anaemia Associated With Chronic Kidney Disease" (1 trials), "COVID-19" (1 trials) and "COVID-19 Pandemic" (1 trials). Many other conditions were trialed in "Hospital Sibu" in a lesser frequency.

Most popular intervention types in "Hospital Sibu" are "Drug" (9 trials), "Biological" (6 trials), "Device" (2 trials), "Other" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Wondaleaf®" (2 trials), "3D laparoscopic cholecystectomy" (1 trials), "AK0529" (1 trials) and "Adalimumab - GP2017" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Sibu" are 19 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Hospital Sibu". undefined are not yet recruiting, 1 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Hospital Sibu, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Sibu, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".